Biohaven Provides Updates on Several Clinical Programs; Shares Rise

MT Newswires Live01-13

Biohaven (BHVN) said Monday that it is "positioned to achieve significant milestones" in 2026 as it provided updates on several of its clinical programs.

Regarding its IgA nephropathy program, the company said it completed a meeting with the US Food and Drug Administration in Q4 2025 to align its study design and expects to begin the trial in early 2026.

The company said that it is planning a study evaluating BHV-1300 in Graves' disease, an autoimmune condition, this year.

Biohaven announced preliminary data in a study evaluating opakalim in an ongoing open-label extension study in focal epilepsy, and said pivotal results from the trial are expected this year.

Regarding its obesity study, the company said it began dosing patients in a phase 2 trial with its myostatin-activin inhibitor for weight loss in Q4 2025, with topline results expected this year.

The company also provided updates on its studies related to cancer, Parkinson's disease, and others.

Biohaven shares were up 10% in recent Monday trading.

Price: 11.47, Change: +0.36, Percent Change: +3.21

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603542729?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-13 00:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603542729","market":"fut","top_or_hot":-1,"title":"Biohaven Provides Updates on Several Clinical Programs; Shares Rise","media":"MT Newswires Live","content":"<html><body><p> Biohaven (BHVN) said Monday that it is \"positioned to achieve significant milestones\" in 2026 as it provided updates on several of its clinical programs.</p><p>Regarding its IgA nephropathy program, the company said it completed a meeting with the US Food and Drug Administration in Q4 2025 to align its study design and expects to begin the trial in early 2026.</p><p>The company said that it is planning a study evaluating BHV-1300 in Graves' disease, an autoimmune condition, this year.</p><p>Biohaven announced preliminary data in a study evaluating opakalim in an ongoing open-label extension study in focal epilepsy, and said pivotal results from the trial are expected this year.</p><p>Regarding its obesity study, the company said it began dosing patients in a phase 2 trial with its myostatin-activin inhibitor for weight loss in Q4 2025, with topline results expected this year.</p><p>The company also provided updates on its studies related to cancer, Parkinson's disease, and others.</p><p>Biohaven shares were up 10% in recent Monday trading.</p><p>Price: 11.47, Change: +0.36, Percent Change: +3.21</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biohaven Provides Updates on Several Clinical Programs; Shares Rise</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiohaven Provides Updates on Several Clinical Programs; Shares Rise\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-01-13 00:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Biohaven (BHVN) said Monday that it is \"positioned to achieve significant milestones\" in 2026 as it provided updates on several of its clinical programs.</p><p>Regarding its IgA nephropathy program, the company said it completed a meeting with the US Food and Drug Administration in Q4 2025 to align its study design and expects to begin the trial in early 2026.</p><p>The company said that it is planning a study evaluating BHV-1300 in Graves' disease, an autoimmune condition, this year.</p><p>Biohaven announced preliminary data in a study evaluating opakalim in an ongoing open-label extension study in focal epilepsy, and said pivotal results from the trial are expected this year.</p><p>Regarding its obesity study, the company said it began dosing patients in a phase 2 trial with its myostatin-activin inhibitor for weight loss in Q4 2025, with topline results expected this year.</p><p>The company also provided updates on its studies related to cancer, Parkinson's disease, and others.</p><p>Biohaven shares were up 10% in recent Monday trading.</p><p>Price: 11.47, Change: +0.36, Percent Change: +3.21</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2603542729","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603542729","pubTimestamp":1768237072,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Biohaven  said Monday that it is \"positioned to achieve significant milestones\" in 2026 as it provided updates on several of its clinical programs.Regarding its IgA nephropathy program, the company said it completed a meeting with the US Food and Drug Administration in Q4 2025 to align its study design and expects to begin the trial in early 2026.The company said that it is planning a study evaluating BHV-1300 in Graves' disease, an autoimmune condition, this year.Biohaven announced preliminary data in a study evaluating opakalim in an ongoing open-label extension study in focal epilepsy, and said pivotal results from the trial are expected this year.Regarding its obesity study, the company said it began dosing patients in a phase 2 trial with its myostatin-activin inhibitor for weight loss in Q4 2025, with topline results expected this year.The company also provided updates on its studies related to cancer, Parkinson's disease, and others.Biohaven shares were up 10% in recent Monday t","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BHVN":"Biohaven Pharmaceutical Holding Co Ltd.","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC"},"translate_title":"Biohaven提供了几个临床项目的更新；股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BHVN":1},"content_text":"Biohaven (BHVN) said Monday that it is \"positioned to achieve significant milestones\" in 2026 as it provided updates on several of its clinical programs.Regarding its IgA nephropathy program, the company said it completed a meeting with the US Food and Drug Administration in Q4 2025 to align its study design and expects to begin the trial in early 2026.The company said that it is planning a study evaluating BHV-1300 in Graves' disease, an autoimmune condition, this year.Biohaven announced preliminary data in a study evaluating opakalim in an ongoing open-label extension study in focal epilepsy, and said pivotal results from the trial are expected this year.Regarding its obesity study, the company said it began dosing patients in a phase 2 trial with its myostatin-activin inhibitor for weight loss in Q4 2025, with topline results expected this year.The company also provided updates on its studies related to cancer, Parkinson's disease, and others.Biohaven shares were up 10% in recent Monday trading.Price: 11.47, Change: +0.36, Percent Change: +3.21","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603542729","isCrawlerRequest":true}